Cytotoxicity

With an emphasis on formulation stability, safety, and clinical compatibility, the current study sought to create and assess stable parenteral emulsions for critical care medicine. Three batches of emulsions were made using pharmaceutical-grade lipids, emulsifiers, and isotonic agents, and the results were compared to control formulations. During a 90-day storage period at 4 °C, 25 °C, and 40 °C, physicochemical parameters such as droplet size, zeta potential, pH, and osmolarity were measured. While statistical analyses (ANOVA and Levene's Test) confirmed reproducibility and consistency across batches, sterility and endotoxin testing guaranteed microbial safety. According to the results, emulsions kept at 4 °C exhibited the best stability, whereas emulsions kept at higher temperatures experienced mild or rapid destabilization. Endotoxin levels were within pharmacopeial limits, and all batches remained sterile. The feasibility of creating stable and safe parenteral emulsions that can be administered intravenously to critically ill patients is highlighted in the study, along with the significance of appropriate storage conditions in maintaining formulation integrity.

Turmeric has been reported to reduce brain volume in mice models, TB positive and intestinal inflammation in mice models. The purpose of the study was to develop and optimize the curcumin-loaded nanostructured lipid carriers (NLCs) by hot high-pressure homogenization method in order to increase its oral bioavailability. The optimized formulation displayed the following properties, a particle size of 165.9 nm, and high entrapment efficiency, strong zeta potential providing physical stability. Sustained release was observed in vitro and in vivo pharmacokinetic analysis showed strongly increased systemic exposure and extended circulation half-life with respect to free curcumin. The study findings validate the findings that NLCs offer a potential delivery vehicle to facilitate enhanced bioavailability of poorly bioavailable bioactives and that NLCs have prospects in pharmaceutical and nutraceutical fields.

The need for alternative drug delivery methods that enhance patient compliance and therapeutic efficacy has been brought to light by the rising incidence of diabetes mellitus and the drawbacks of traditional oral therapy. In order to improve bioavailability by avoiding first-pass metabolism, this study concentrated on the formulation, development, and assessment of mucoadhesive buccal tablets of metformin hydrochloride. Using the direct compression method, five formulations (F1–F5) were created with different concentrations of the mucoadhesive polymers sodium alginate, HPMC, and carbopol 934. Physical characteristics, mucoadhesive strength, swelling index, surface pH, uniformity of drug content, and in-vitro drug release over an 8-hour period were all assessed for the tablets. With the best mechanical strength, the highest mucoadhesion (30.4 g), the most sustained drug release (93.7%), and controlled swelling (68%), formulation F5 outperformed the others. Significant variations between formulations were validated by statistical analysis employing ANOVA and Tukey HSD, confirming the influence of polymer concentration on drug release kinetics. According to the study's findings, mucoadhesive buccal tablets present a viable and patient-friendly substitute for the regulated administration of medications such as metformin hydrochloride, which are used to treat diabetes.